bo_Khaled قال:
جميل و مشجع ولكن يجب معرفة تفاصيل أكثر عن الشركة و وضعها المالي ..
يرجى ذكر إسم الشركه مع جزيل الشكر و الإمتنان ..
ابو خالد السهم AMLN
شوفوا كلام ملتي فوول قبل التحليل
You can find a similar example looking at Amylin Pharmaceuticals (Nasdaq: AMLN), which has struggled for years with clinical and regulatory setbacks on its diabetes drug Pramlintide. Once described as "a typical cautionary tale from the biotech front" because of a seemingly devastatingly clinical failure with Pramlintide, the company now trades near all-time highs. Amazingly, neither Pramlintide nor any other Amylin drug has yet to reach the market -- although that may all change in a few months, if the Food and Drug Administration can be persuaded to give Pramlintide or another drug, called Exanatide, the green light.
